Immune checkpoint inhibitors targeting the CLTA-4 and PD-L1/PD-1 pathways have been proven to enhance anti-tumor immune responses, which indicates a promising strategy for cancer treatment, including for PC [16,17]. The gene discussed is CD274; the disease is cancer.